News & Events

News


Wednesday May 09, 2018

Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference

Live Audio Webcast Will be on May 15, 2018 SAN DIEGO, May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 15, 2018, in Las Vegas, Nevada. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. About Neurocrine Biosciences, Inc. N...


Tuesday May 08, 2018

Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics

- Nearly 28 Percent of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia - Over Half of Patients with Possible Tardive Dyskinesia Experienced Uncontrollable Movements in Two or More Body Regions - New Data from KINECT 4 Study Show Long-Term Treatment with INGREZZA® (valbenazine) Capsules Provided Sustained, Clinically Meaningful Improvement in Tardive Dyskinesia and was Well-Tolerated SAN DIEGO, May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), p...


Wednesday May 02, 2018

Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting

New Data Provide Insight Into the Real-World Impact of Potential Tardive Dyskinesia in Patients Treated With Antipsychotic Medicines New Data From KINECT 4 Study Describe the Results of Long-Term INGREZZA® (valbenazine) Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated w...


Monday April 30, 2018

Neurocrine Biosciences Reports First Quarter 2018 Financial Results

INGREZZA® (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads to Expansion of Sales Force Increased Investment in Tourette Syndrome Clinical Program with Initiation of T-Force PLATINUM Study Two Positive Phase III Clinical Study Results for Elagolix in Uterine Fibroids, NDA Anticipated in 2019 SAN DIEGO, April 30, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the first quarter 2018, and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs.   "We have had a tremendous start to 2018 with...


Friday April 27, 2018

AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids- Primary and secondary efficacy and safety data to be presented from two extension Phase 3 studies evaluating the use of elagolix in women with endometriosis with associated moderate to severe pain- New productivity data from a Phase 2b study evaluating elagolix in women with uterine fibroids will also be presentedNORTH CHICAGO, Ill., April 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data  for elagolix, an investigational, orally administered...

Events